Palvella Therapeutics, Inc
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to tr… Read more
Palvella Therapeutics, Inc (PVLA) - Total Liabilities
Latest total liabilities as of September 2025: $28.25 Million USD
Based on the latest financial reports, Palvella Therapeutics, Inc (PVLA) has total liabilities worth $28.25 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Palvella Therapeutics, Inc - Total Liabilities Trend (2020–2024)
This chart illustrates how Palvella Therapeutics, Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Palvella Therapeutics, Inc Competitors by Total Liabilities
The table below lists competitors of Palvella Therapeutics, Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bank Ina Perdana PT
JK:BINA
|
Indonesia | Rp26.54 Trillion |
|
Horizon Bancorp
NASDAQ:HBNC
|
USA | $5.75 Billion |
|
Hubei DOTI Micro Technology Co. Ltd.
SHE:301183
|
China | CN¥413.18 Million |
|
Ufuk Yatirim Yonetim Ve Gayrimenkul AS
IS:UFUK
|
Turkey | TL234.06 Million |
|
Zhejiang Supor Co Ltd
SHE:002032
|
China | CN¥7.06 Billion |
|
KMDHF
PINK:KMDHF
|
USA | $60.05 Billion |
|
Golden Ocean Group Ltd
NASDAQ:GOGL
|
USA | $1.57 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Palvella Therapeutics, Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Palvella Therapeutics, Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Palvella Therapeutics, Inc (2020–2024)
The table below shows the annual total liabilities of Palvella Therapeutics, Inc from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $25.63 Million | +124.25% |
| 2023-12-31 | $11.43 Million | -71.21% |
| 2022-12-31 | $39.70 Million | -61.39% |
| 2021-12-31 | $102.81 Million | +38.96% |
| 2020-12-31 | $73.98 Million | -- |